2,3-Disubstituted 6-azabicyclo[3.2.1]octanes as novel dopamine transporter inhibitors

Josefina Quirante, Xavier Vila, Josep Bonjoch, Alan P. Kozikowski, Kenneth M. Johnson

Research output: Contribution to journalArticlepeer-review

19 Scopus citations


A series of cis and trans 3β-aryl-2-carbomethoxy-6-azabicyclo[3.2.1] octanes, with different substitution at the para-position of the aryl group, were synthesized and examined for reuptake inhibition at the dopamine transporter (DAT). The potency for inhibition of DA reuptake was compared with that of cocaine to determine the significance of the replacement of the 8-azabicyclo[3.2.1]octane (tropane nucleus), displayed in cocaine, for the 6-azabicyclo[3.2.1]octane (normorphan framework). This bicyclic core structure constitutes a novel chemical scaffold in DAT inhibitor design, which may provide new insights into the 3D structure of the DAT and its interaction with cocaine and DA. Among these compounds, the trans-amine series 8 were the most potent ligands at the DAT. In particular, the normorphan analogue 8c (bearing a p-chloro substituent at the β-aryl group, IC50=452 nM) displayed a potency that is in the same range as cocaine (IC50=459 nM) itself.

Original languageEnglish (US)
Pages (from-to)1383-1391
Number of pages9
JournalBioorganic and Medicinal Chemistry
Issue number6
StatePublished - Mar 15 2004
Externally publishedYes


  • 6-Azabicyclo[3.2.1]octane
  • Cocaine
  • Dopamine uptake
  • Normorphan analogues

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Organic Chemistry
  • Drug Discovery
  • Pharmaceutical Science


Dive into the research topics of '2,3-Disubstituted 6-azabicyclo[3.2.1]octanes as novel dopamine transporter inhibitors'. Together they form a unique fingerprint.

Cite this